Today's news: Let's take a realistic look at this. The MJF Foundation sponsored this. It was a mouse study. If one desires to resort to scare tactics or if one wishes to attack this, you may hear a lot of noise about it being a mouse study. However, that, a mouse experiment, is customarily a beginning point for a drug study, but this situation is different because of the AVXL 2-73 clinical trial in humans, which has established safety and delved into dosage as well as indicated signs of efficacy. All of the latter is significant!
Also, this mouse study for Parkinson's is an MJF Foundation (MJF) project. MJF is interested in finding effective treatments for Parkinson's not in promoting a single company. This foundation does its due diligence before wasting its resources on pursuing a study. The study illustrated promise. MJF would be remiss in its purpose and existence if it did not follow through once it found something that is encouraging (Shows Efficacy to Support Potential Disease Modification in Parkinson’s Disease).
This is what Professor Harald Hampel, MD, Ph.D., based on clinical data from our ongoing human trial said about AVXL in July of this year:
“This clinical data together with prior preclinical findings seem to confirm ANAVEX 2-73’s selective activation of the specific stress reducing and survival protein, Sigma-1 receptor. This seems to present a potential common pathway for rescuing major neurodevelopmental and neurodegenerative disease mechanisms, like in Autism-related disorders and Alzheimer’s disease. I believe the distinct mechanistic nature suggests the compound could be a candidate treatment for a precision medicine approach across a spectrum of different neurological and psychiatric diseases,” said Professor Harald Hampel, MD, PhD, Professor and AXA Research Fund Chair at Sorbonne Universities’ Pierre and Marie Curie University (UPMC), Paris, France and member of Anavex’s Scientific Advisory Board."
As I and others have said in earlier posts, Anavex has a drug pipeline other than AVXL 2-73, but AVXL 2-73 has potential for multiple applications. Anavex has come a long way. I believe it is important to keep all of this, and more, in mind other than worrying about the day to day, hour by hour or minute to minute fluctuations in the share price.
The MJF development is a real feather in the Anavex cap although Anavex has a way to go! Anavex is still speculative for longs OR SHORTS. But, it is a better bet for me, a long, than it was when I first bought its shares.
